Stonegate Capital Partners has updated its coverage on Alpha Cognition Inc. (NASDAQ: ACOG), highlighting a strong second quarter for the company's lead product, ZUNVEYL. The company reported net product revenue of $6.0 million, a 71% increase quarter-over-quarter, with bottles dispensed rising 37% to 8,294. June was the strongest month since launch, with 2,997 bottles dispensed. Importantly, the growth was achieved without material stocking benefits or additional formulary wins, indicating that underlying demand and commercial execution are driving the results.
The quarter's quality is notable given that downstream PBM implementation remains at approximately 16%. Despite this limited payer access, prescriptions, repeat use, and facility adoption all advanced. Specifically, the company saw 1,347 quarterly prescribers, 1,024 repeat prescribers, and 1,908 cumulative writers. Additionally, 1,095 long-term care facilities generated prescriptions during the quarter. This broadening adoption and deepening utilization suggest a solid growth trajectory even before broader payer coverage is realized.
Alpha Cognition continues to balance commercial investment with a growing evidence base. The company lowered its FY26 R&D and SG&A guidance to $50M-$54M while maintaining its 2027 operating profitability target. Several key milestones are anticipated in the near term, including CONVERGE data expected in 3Q26, the ongoing RESOLVE trial, and the sublingual program, which is gated by comparative PK results. These developments could provide additional catalysts for the company as it moves toward greater operating leverage.
According to Stonegate, the core setup for Alpha Cognition is increasingly about breadth, depth, and payer upside. Significant white space remains across homes and physicians, utilization is deepening, and broader PBM implementation remains an incremental growth driver. The company's ability to scale demand in a constrained access environment underscores the potential for further growth as payer coverage expands.
For more details, you can view the full announcement at Stonegate's website. Stonegate Capital Partners provides investor relations, equity research, and institutional investor outreach services for public companies. Their affiliate, Stonegate Capital Markets, offers investment banking services.
